Related Experiment Video
Updated: Nov 1, 2025
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
COVID-19 Vaccines in Patients With Chronic Liver Disease
Anand Sharma1, Itish Patnaik1, Ashok Kumar1
1Department of Gastroenterology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Insights
Patients with chronic liver disease (CLD) face higher COVID-19 risks. While vaccines are safe for the general population, data on CLD patients is limited, necessitating further research on vaccine efficacy and safety in this group.
Area of Science:
- Hepatology
- Infectious Diseases
- Vaccinology
Background:
- The COVID-19 pandemic poses significant risks to patients with chronic liver disease (CLD) due to inherent immune dysfunction.
- Individuals with CLD exhibit increased morbidity and mortality rates when infected with SARS-CoV-2.
Purpose of the Study:
- To review the current understanding of COVID-19 vaccine safety and efficacy in patients with chronic liver disease.
- To highlight the scarcity of data regarding this specific patient population in major vaccine trials.
Main Methods:
- Review of existing literature on COVID-19 vaccines and clinical trials.
- Analysis of data from phase 2/3 trials regarding patient demographics and reported adverse events.
- Examination of guidelines issued by liver societies concerning vaccination in CLD patients.
Main Results:
- Current phase 2/3 vaccine trials show general safety and efficacy but include limited numbers of CLD patients.
- No specific liver-related adverse effects have been reported in the available trial data.
- Liver societies recommend prioritizing COVID-19 vaccination for individuals with CLD.
Conclusions:
- Vaccination against COVID-19 is recommended for patients with chronic liver disease.
- Further clinical trials are essential to comprehensively assess the safety and efficacy of SARS-CoV-2 vaccines in the CLD population.
Abstract:
The COVID-19 pandemic has caused mayhem globally since the beginning of 2020. Owing to the immune dysfunction inherent to cirrhosis and the poor general condition, patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19. Recently, a number of vaccines against SARS-Cov-2 have been approved for emergency use around the globe. Although the phase 2/3 trials of these vaccines show them to be safe and effective in the general population, data in patients with CLD are scarce. The number of patients with CLD enrolled on these trials is small, and no liver-related adverse effects have been reported yet. Various liver societies have come up with guidelines on vaccination in this population and recommend vaccination on a priority basis. Trials to assess the safety and efficacy of the COVID vaccines are underway and are likely to provide valuable insight into this matter.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...